Bayer

Bayer submits NDA for regorafenib for gastrointestinal stromal tumors

Friday, August 31, 2012 12:02 PM

Bayer HealthCare and Onyx Pharmaceuticals, a global biopharmaceutical company based in San Francisco, have submitted a New Drug Application (NDA) to the FDA for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.

More... »

Bayer and Covance form strategic partnership

Thursday, May 31, 2012 10:52 AM

Bayer HealthCare and Covance, a CRO based in Princeton, N.J., have established a long-term strategic partnership in the area of clinical drug development including R&D services related to phase II-IV clinical studies and central laboratory services.

More... »

Synthetic Biologics appoints Carol Reed as senior vice president

Thursday, May 17, 2012 11:12 AM

Synthetic Biologics, an Ann Arbor, Mich.-based developer of synthetic DNA-based therapeutics and disease-modifying medicines for serious illnesses, has appointed Carol Reed, M.D., as senior vice president of clinical & regulatory affairs.

More... »

Piramal nabs Bayer's molecular imaging development portfolio

Monday, April 16, 2012 12:18 PM

India-based Piramal Healthcare has acquired worldwide rights to Bayer Pharmaceuticals’ molecular imaging research and development portfolio through Piramal Imaging, its newly created subsidiary.

More... »

Genesis Biopharma names Bishop executive chairman

Friday, March 23, 2012 03:12 PM

Genesis Biopharma, a biotechnology company developing targeted cancer immunotherapies, appointed Hans E. Bishop executive chairman of the company's board of directors.

More... »

Dr. Stephen Chen named chairman, CEO of Amarillo

Monday, February 27, 2012 10:10 AM

Amarillo Biosciences, a U.S. biotechnology firm, has appointed Dr. Stephen T. Chen CEO and chairman of the board.

More... »

Bayer initiates expanded access program for radium-223 chloride

Monday, February 6, 2012 02:11 PM

The FDA has approved of Bayer Healthcare proceeding with its expanded access program to provide the investigational drug radium-223 chloride to patients diagnosed with castration-resistant prostate cancer (CRPC) and hormone-refractory prostate cancer (HRPC) with symptomatic bone metastases.

More... »

International collaboration to combat 10 neglected tropical diseases by 2020

Monday, January 30, 2012 03:49 PM

Thirteen pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organizations will join forces to eliminate or control 10 neglected tropical diseases (NTDs) by the end of the decade.

More... »

Bayer, Ventana collaborate on test for personalized cancer therapy

Wednesday, January 18, 2012 12:05 PM

Bayer Pharma has collaborated with Ventana Medical Systems, a member of the Roche Group, to develop a molecular companion diagnostic test to identify patients most likely to benefit from a novel Bayer antibody-drug conjugate (ADC).

More... »

Regeneron, Bayer initiate phase III SIGHT trial in China

Monday, November 28, 2011 10:30 AM

Regeneron Pharmaceuticals and Bayer HealthCare have initiated a phase III clinical trial evaluating the efficacy and safety of EYLEA (aflibercept) injection in the neovascular form of age-related macular degeneration (wet AMD) in China.

More... »